The role of antimicrobial peptides at the ocular surface

Ophthalmic Research

Volumn 41, Issue 2, 2009, Pages 60-75

  McDermott, Alison M ^a  

^a UNIVERSITY OF HOUSTON   (United States)

Author keywords

Cathelicidin; Defensin; Infection; LL 37; Wound healing

Indexed keywords

ALPHA DEFENSIN; BETA DEFENSIN; BETA DEFENSIN 3; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CECROPIN A; CXCL1 CHEMOKINE; HEPCIDIN; HISTATIN; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MELITTIN; POLYPEPTIDE ANTIBIOTIC AGENT; RETROCYCLIN 2; STATHERIN; THYMOSIN BETA4; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIMICROBIAL THERAPY; ANTIVIRAL ACTIVITY; CELL INFILTRATION; CONJUNCTIVA EPITHELIUM; CORNEA EPITHELIUM; DRUG MECHANISM; EPITHELIUM CELL; HERPES SIMPLEX KERATITIS; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; INFECTION PREVENTION; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PSEUDOMONAS INFECTION; REVIEW; STIMULUS RESPONSE; WOUND HEALING;

ALPHA-DEFENSINS; ANIMALS; ANTI-INFECTIVE AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; CONJUNCTIVA; CORNEA; EPITHELIAL CELLS; HUMANS;

EID: 58149103363     PISSN: 00303747     EISSN: None     Source Type: Journal    
DOI: 10.1159/000187622     Document Type: Review

References (217)

1. Ganz T: Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 2003;3:710-720.
2. Tang YQ, Yuan J, Osapay G, Osapay K, Tran D, Miller CJ, Ouellette AJ, Selsted ME: A cyclic antimicrobial produced in primate leukocytes by the ligation of two truncated alpha-defensins. Science 1999;286:498-502.
3. Leonova L, Kokryakov VN, Aleshina G, Hong T, Nguyen T, Zhao C, Waring AJ, Lehrer RL: Circular minidefensins and posttranslational generation of molecular diversity. J Leukoc Biol 2001;70:461-464.
4. Tran D, Tran PA, Tang YQ, Yuan J, Cole T, Selsted ME: Homodimeric theta-defensins from Rhesus macaque leukocytes: isolation, synthesis, antimicrobial activities, and bacterial binding properties of the cyclic peptides. J Biol Chem 2002;277:3079-3084.
5. Nguyen TX, Cole AM, Lehrer RI: Evolution of primate theta-defensins: a serpentine path to a sweet tooth. Peptides 2003;24:1647-1654.
6. Ganz T, Selsted ME, Szklarek D, Harwig SS, Daher K, Bainton DF, Lehrer RI: Defensins. Natural peptide antibiotics of human neutrophils. J Clin Invest 1985;76:1427-1435.
7. Selsted ME, Harwig SS, Ganz T, Schilling JW, Lehrer RI: Primary structures of three human neutrophil defensins. J Clin Invest 1985;76:1436-1439.
8. Wilde CG, Griffith JE, Marra MN, Snable JL, Scott RW: Purification and characterization of human neutrophil peptide-4, a novel member of the defensin family. J Biol Chem 1989;264:11200-11203.
9. Faurschou M, Sorensen OE, Johnsen AH, Askaa J, Borregaard N: Defensin-rich granules of human neutrophils: characterization of secretory properties. Biochim Biophys Acta 2002;1591:29-35.
10. Ganz T: Extracellular release of antimicrobial defensins by human polymorphonuclear leukocytes. Infect Immun 1987;55:568-571.
11. Daher KA, Lehrer RI, Ganz T, Kronenberg M: Isolation and characterization of human defensin cDNA clones. Proc Natl Acad Sci USA 1988;85:7327-7331.
12. Valore EV, Ganz T: Posttranslational processing of defensins in immature human myeloid cells. Blood 1992;79:1538-1544.
13. Liu L, Ganz T: The pro region of human neutrophil defensin contains a motif that is essential for normal subcellular sorting. Blood 1995;85:1095-1103.
14. Valore EV, Martin E, Harwig SS, Ganz T: Intramolecular inhibition of human defensin HNP-1 by its propiece. J Clin Invest 1996;97:1624-1629.
15. Wu Z, Li X, Ericksen B, de Leeuw E, Zou G, Zeng P, Xie C, Li C, Lubkowski J, Lu WY, Lu W: Impact of pro segments on the folding and function of human neutrophil alpha-defensins. J Mol Biol 2007;368:537-549.
16. Agerbeth B, Charo J, Werr J, Olsson B, Idali F, Lindbom L, Kiessling R, Jornvall H, Wigzell H, Gudmundsson GH: The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. Blood 2000;96:3086-3093.
17. Rodriguez-Garcia M, Oliva H, Climent N, Garcia F, Gatell JM, Gallart T: Human immature monocyte-derived dendritic cells produce and secrete alpha defensins 1-3. J Leukoc Biol 2007;82:1143-1146.
18. Tan BH, Meinken C, Bastian M, Bruns H, Legaspi A, Ochoa MT, Krutzik SR, Bloom BR, Ganz T, Modlin RL, Stenger S: Macrophages acquire neutrophil granules for antimicrobial activity against intracellular pathogens. J Immunol 2006;177:1864-1871.
19. Jones DE, Bevins CL: Paneth cells of the human small intestine express an antimicrobial peptide gene. J Biol Chem 1992;267:23216-23225.
20. Jones DE, Bevins CL: Defensin-6 mRNA in human Paneth cells: implications for antimicrobial peptides in host defense of the human bowel. FEBS Lett 1993;315:187-192.
21. Quayle AJ, Porter EM, Nussbaum AA, Wang YM, Brabec C, Yip KP, Mok SC: Gene expression, immunolocalization and secretion of human defensin-5 in human female reproductive tract. Am J Pathol 1998;152:1247-1258.
22. Frye M, Bargon J, Dauletbaev N, Weber A, Wagner TO, Gropp R: Expression of human alpha-defensin 5 (HD5) mRNA in nasal and bronchial epithelial cells. J Clin Pathol 2000; 53:770-773.
23. Ghosh D, Porter E, Shen B, Lee SK, Wilk D, Drazba J, Yadav SP, Crabb JW, Ganz T, Bevins CL: Paneth cell trypsin is the processing enzyme for human defensin-5. Nat Immunol 2002;3:583-590.
24. Linzmeier R, Ho CH, Hoang BV, Ganz T: A 450-kb contig of defensin genes on human chromosome 8p23. Gene 1999;233:205-211.
25. Linzmeier R, Michaelson D, Liu L, Ganz T: The structure of neutrophil defensin genes. FEBS Lett 1993;321:267-273.
26. Mallow EB, Harris A, Salzman N, Russell JP, DeBerardinis RJ, Ruchelli E, Bevins CL: Human enteric defensins. Gene structure and developmental expression. J Biol Chem 1996;271:4038-4045.
27. Mars WM, Patmasiriwat P, Maity T, Huff V, Weil MM, Saunders GF: Inheritance of unequal numbers of the genes encoding the human neutrophil defensins HP-1 and HP-3. J Biol Chem 1995;270:30371-30376.
28. Aldred PMR, Hollox EJ, Armour JAL: Copy number polymorphism and expression level variation of the human α -defensin genes DEFA1 and DEFA3. Hum Mol Genet 2005;14:2045-2052.
29. Linzmeier RM, Ganz T: Human defensin gene copy number polymorphisms: comprehensive analysis of independent variation in α- and β-defensin regions at 8p22-p23. Genomics 2005;86:423-430.
30. Ballana E, Gonzalez JR, Bosch N, Estivill X: Inter-population variability of DEFA3 gene absence: correlation with haplotype structure and population variability. BMC Genomics 2007;8:14.
31. Duits LA, Ravensbergen B, Rademaker M, Hiemstra PS, Nibbering PH: Expression of beta-defensin 1 and 2 mRNA by human monocytes, macrophages and dendritic cells. Immunology 2002;106:517-525.
32. Ryan LK, Diamond G, Amrute S, Feng Z, Weinberg A, Fitzgerald-Bocarsly P: Detection of HBD1 peptide in peripheral blood mononuclear cell subpopulations by intracellular flow cytometry. Peptides 2003;24:1785-1794.
33. Bensch KW, Raida M, Magert HJ, Schulz-Knappe P, Forssmann WG: hBD-1: a novel beta-defensin from human plasma. FEBS Lett 1995;368:331-335.
34. McCray PB, Bentley L: Human airway epithelia express a beta-defensin. Am J Respir Cell Mol Biol 1997;16:343-349.
35. Valore EV, Park CH, Quayle AJ, Wiles KR, McCray PB, Ganz T: Human beta-defensin-1: an antimicrobial peptide of urogenital tissues. J Clin Invest 1998;101:1633-1642.
36. Paulsen FP, Pufe T, Schaudig U, Held-Feindt J, Lehmann J, Schroder JM, Tillmann BN: Detection of natural peptide antibiotics in human nasolacrimal ducts. Invest Ophthalmol Vis Sci 2001;42:2157-2163.
37. Jia HP, Starner T, Ackermann M, Kirby P, Tack BF, McCray PB: Abundant human beta-defensin-1 expression in milk and mammary gland epithelium. J Pediatr 2001;38:109-112.
38. Harder J, Bartels J, Christophers E, Schroder JM: A peptide antibiotic from human skin. Nature 1997;387:861.
39. O'Neil DA, Porter EM, Elewaut D: Expression and regulation of the human beta-defensins hBD-1 and hBD-2 in intestinal epithelium. J Immunol 1999;163:6718-6724.
40. Wada A, Ogushi K, Kimura T, Hojo H, Mori N, Suzuki S, Kumatori A, Se M, Nakahara Y, Nakamura M, Moss J, Hirayama T: Helicobacter pylori-mediated transcriptional regulation of the human beta-defensin-2 gene requires NF-κB. Cell Microbiol 2001;3:115-123.
41. Wang X, Zhang Z, Louboutin JP, Moser C, Weiner DJ, Wilson JM: Airway epithelia regulate expression of human beta-defensin-2 through Toll-like receptor 2. FASEB J 2003;17:1727-1729.
42. Harder J, Bartels J, Christophers E, Schröder JM: Isolation and characterization of human-beta-defensin-3, a novel inducible peptide antibiotic. J Biol Chem 2001;276:5707-5713.
43. Garcia JR, Jaumann F, Schulz S, Krause A, Rodriguez-Jimenez J, Forssmann U, Adermann K, Kluver E, Vogelmeier C, Becker D, Hedrich R, Forssmann WG, Bals R: Identification of a novel, multifunctional beta-defensin (human beta-defensin 3) with specific antimicrobial activity. Its interaction with plasma membranes of Xenopus oocytes and the induction of macrophage chemoattraction. Cell Tissue Res 2001;306:257-264.
44. Garcia JR, Krause A, Schulz S, Rodriguez-Jimenez J, Kluver E, Adermann K, Forssmann U, Frimpong-Boateng A, Bals R, Forssmann WG: Human beta-defensin 4: a novel inducible peptide with a salt-sensitive spectrum of antimicrobial activity. FASEB J 2001;15:1819-1821.
45. Yamaguchi Y, Nagase T, Makita R, Fukuhara S, Tomita T, Tominaga T, Kurihara H, Ouchi Y: Identification of multiple novel epididymis specific beta-defensin isoforms in humans and mice. J Immunol 2002;169:2516-2523.
46. Liu L, Wang L, Jia HP, Zhao C, Heng HH, Schutte BC, McCray PB Jr, Ganz T: Structure and mapping of the human beta-defensin HBD-2 gene and its expression at sites of inflammation. Gene 1998;222:237-244.
47. Diamond G, Kaiser V, Rhodes J, Russel JP, Bevins CL: Transcriptional regulation of beta-defensin gene expression in tracheal epithelial cells. Infect Immun 2000;68:113-119.
48. Harder J, Meyer-Hoffert U, Teran LM, Schwichtenberg L, Bartels J, Maune S, Schröder JM: Mucoid Pseudomonas aeruginosa, TNF alpha, and IL-beta, but not IL-6, induce human beta-defensin-2 in respiratory epithelia. Am J Respir Cell Mol Biol 2000;22:714-721.
49. Liu L, Zhao C, Heng HH, Ganz T: The human beta-defensins-1 and alpha defensins are encoded by adjacent genes: two peptide families with differing disulfide topology share a common ancestry. Genomics 1997;43:316-320.
50. Schutte BC, Mitros JP, Bartlett JA, Walters JD, Jia HP, Welsh MJ, Casavant TL, McCray PB Jr: Discovery of five conserved beta-defensin gene clusters using a computational search strategy. Proc Natl Acad Sci USA 2002;99:2129-2133.
51. Patil AA, Cai Y, Sang Y, Blecha F, Zhang G: Cross-species analysis of the mammalian beta-defensin gene family: presence of syntenic gene clusters and preferential expression in the male reproductive tract. Physiol Genomics 2005;23:5-17.
52. Rodriguez-Jimenez FJ, Krause A, Schultz S, Forssmann WG, Conejo-Garcia JR, Schreeb R, Motzkus D: Distribution of new human beta-defensin genes clustered on chromosome 20 in functionally different segments of epididymis. Genomics 2003;81:175-183.
53. Yenugu S, Hamil KG, Radhakrishnan Y, French FS, Hall SH: The androgen-regulated epididymal sperm-binding protein, human beta-defensin 118 (DEFB118) (formerly ESC42), is an antimicrobial beta-defensin. Endocrinology 2004;145:3165-3173.
54. Premratanachai P, Joly S, Johnson SK, Mc-Cray PB, Jia HP, Guthmiller JM: Expression and regulation of novel human beta-defensins in gingival keratinocytes. Oral Microbiol Immunol 2004;19:111-117.
55. Kao CY, Chen Y, Zhao YH, Wu R: OR Feome-based search of airway epithelial cell-specific novel human beta-defensin genes. Am J Respir Cell Mol Biol 2003;29:71-80.
56. Hollox EJ, Armour JAL, Barber JCK: Extensive normal copy number variation of a β-defensin antimicrobial-gene cluster. Am J Hum Genet 2003;73:591-600.
57. Matsushita I, Hasegawa K, Nakata K, Yasuda K, Tokinaga K, Keicho N: Genetic variants of human beta-defensin-1 and chronic obstructive pulmonary disease. Biochem Biophys Res Commun 2002;291:17-22.
58. Levy H, Raby BA, Lake S, Tantisira KG, Kwiatkowski D, Lazarus R, Silverman EK, Richter B, Klimecki WT, Vercelli D, Martinez FD, Weiss ST: Association of defensin beta-1 gene polymorphisms with asthma. J Allergy Clin Immunol 2005;115:252-258.
59. Donald CD, Sun CQ, Lim SD, Macosaka J, Cohen C, Amin MB, Yound AN, Ganz TA, Marshall FF, Petros JA: Cancer specific loss of β-defensin 1 in renal and prostatic carcinomas. Lab Invest 2003;83:501-505.
60. Carter J, Churchill AJ, Gorman C, Haynes R: A case of bilateral endophthalmitis and carriage of beta-defensin 1 44CC genotype. Br J Ophthalmol 2007;91:1249-1250.
61. Zanetti M, Gennaro R, Romeo D: Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett 1995;374:1-5.
62. Ritonja A, Kopitar M, Jerala R, Turk V: Primary structure of a new cysteine proteinase inhibitor from pig leukocytes. FEBS Lett 1989;255:211-214.
63. Agerberth B, Gunne H, Odeberg J, Kogner P, Boman HG, Gudmundsson GH: FALL-39, a putative human peptide antibiotic, is cysteine-free and expressed in bone marrow and testis. Proc Natl Acad Sci USA 1995;92:195-199.
64. Cowland J, Johnsen A, Borregaard N: hCAP-18, a cathelin/pro-bactenecin- like protein of human neutrophil specific granules. FEBS Lett 1995;368:173-176.
65. Larrick J, Hirata M, Balint R, Lee J, Zhong J, Wright SC: Human CAP 18: a novel antimicrobial lipopolysaccharide-binding protein. Infect Immun 1995;63:1291-1297.
66. Gudmundsson GH, Agerberth B, Odeberg J, Bergman T, Olsson B, Salcedo R: The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. Eur J Biochem 1996;238:325-332.
67. Linzmeier RM, Ganz T: Copy number polymorphisms are not a common feature of innate immune genes. Genomics 2006;88:122-126.
68. Bals R, Wilson JM: Cathelicidins - a family of multifunctional antimicrobial peptides. Cell Mol Life Sci 2003;60:711-720.
69. Larrick JW, Morgan JG, Palings I, Hirata M, Yen MH: Complementary DNA sequence of rabbit CAP18 - a unique lipopolysaccharide binding protein. Biochem Biophys Res Commun 1991;179:170-175.
70. Sorensen OE, Follin P, Johnsen AH, Calafat J, Tjabringa GS, Hiemstra PS, Borregaard N: Human cathelicidin, hCAP18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood 2001;97:3951-3959.
71. Di Nardo A, Vitiello A, Gallo RL: Mast cell antimicrobial activity is mediated by expression of cathelicidin antimicrobial peptide. J Immunol 2003;170:2274-2278.
72. Bals R, Wang X, Zasloff M, Wilson JM: The peptide antibiotic LL-37/hCAP18 is expressed in epithelia of the human lung where it has broad spectrum antimicrobial activity at the airway surface. Proc Natl Acad Sci USA 1998;95:9541-9546.
73. Frohm M, Agerberth B, Ahangari G, Stahle-Backdahl M, Liden S, Wigzell H, Gudmundsson GH: The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders. J Biol Chem 1997;272:15258-15263.
74. Frohm-Nilsson M, Sandstedt B, Sorensen O, Weber G, Borregaard N, Stahle-Backdahl M: The human cationic antimicrobial protein (hCAP18), a peptide antibiotic, is widely expressed in human squamous epithelia and colocalizes with interleukin-6. Infect Immun 1999;67:2561-2566.
75. Murakami M, Ohtake R, Dorschner B, Schittek B, Garbe C, Gallo RL: Cathelicidin antimicrobial peptide expression in sweat, an innate defence system for the skin. J Invest Dermatol 2002;119:1090-1095.
76. 3 is a direct inducer of antimicrobial peptide gene expression. J Immunol 2004;173:2909-2912.
77. Ooi EH, Wormald PJ, Carney AS, James CL, Tan LW: Fungal allergens induce cathelicidin LL-37 expression in chronic rhinosinusitis patients in a nasal explant model. Am J Rhinol 2007;21:367-372.
78. Li Q, Kumar A, Gui JF, Yu FS: Staphylococcus aureus lipoproteins trigger human corneal epithelial innate response through toll-like receptor-2. Microb Pathog 2008;44:426-434.
79. Zaiou M, Nizet V, Gallo RL: Antimicrobial and protease inhibitory functions of the human cathelicidin (hCAP18/LL-37) prosequence. J Invest Dermatol 2003;120:810-816.
80. Murakami M, Lopez-Garcia B, Braff M, Dorschner RA, Gallo RL: Postsecretory processing generates multiple cathelicidins for enhanced topical antimicrobial defense. J Immunol 2004;172:3070-3077.
81. Yamasaki K, Schauber J, Coda A, Lin H, Dorschner RA, Schecter NM, Bonnart C, Descargues P, Hovnanian A, Gallo RL: Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. FASEB J 2006;20:2068-2080.
82. Krause A, Neitz S, Magert HJ, Schulz A, Forssmann WG, Schulz-Knappe P, Adermann K: LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett 2000;480:147-150.
83. Park CH, Valore EV, Waring AJ, Ganz T: Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001;276:7806-7810.
84. Krause A, Sillard R, Kleemeier B, Kluver E, Maronde E, Conejo-Garcia JR, Forssmann WG, Schulz-Knappe P, Nehls MC, Wattler F, Wattler S, Adermann K: Isolation and biochemical characterization of LEAP-2, a novel blood peptide expressed in the liver. Protein Sci 2003;12:143-152.
85. Ganz T: Hepcidin - a peptide hormone at the interface of innate immunity and iron metabolism. Curr Top Microbiol Immunol 2006;306:183-198.
86. Schittek B, Hipfel R, Sauer B, Bauer J, Kalbacher H, Stevanovic S, Schirle M, Schroder K, Blin N, Meier F, Rassner G, Garbe C: Dermcidin: a novel antibiotic peptide secreted by sweat glands. Nat Immunol 2001;2:1133-1137.
87. Kavanagh K, Dowd S: Histatins: antimicrobial peptides with therapeutic potential. J Pharm Pharmacol 2004;56:285-289.
88. Tang YQ, Yeaman MR, Selsted ME: Antimicrobial peptides from human platelets. Infect Immun 2002;277:37647-37654.
89. Cole AM, Ganz T, Liese AM, Burdick MD, Liu L, Strieter RM: Cutting edge: IFN-inducible ELR-CXC chemokines display defensin-like antimicrobial activity. J Immunol 2001;167:623-627.
90. Yang D, Chen Q, Hoover DM, Staley P, Tucker KD, Lubkowski J, Oppenheim JJ: Many chemokines including CCL20/MIP-3alpha display antimicrobial activity. J Leukoc Biol 2003;74: 448-455.
91. Radek K, Gallo RL: Antimicrobial peptides: natural effectors of the innate immune system. Semin Immunopathol 2007;29:27-43.
92. Gottsch JD, Li Q, Ashraf MF, O'Brien TP, Stark WJ, Liu SH: Defensin gene expression in the cornea. Curr Eye Res 1998;17:1082-1086.
93. Haynes RJ, Tighe PJ, Dua HS: Innate defence of the eye by antimicrobial defensin peptides. Lancet 1998;352:451-452.
94. Haynes RJ, Tighe PJ, Dua HS: Antimicrobial defensin peptides of the human ocular surface. Br J Ophthalmol 1999;83:737-741.
95. Zhou L, Huang LQ, Beuerman RW, Grigg ME, Li SF, Chew FT, Ang L, Stern ME, Tan D: Proteomic analysis of human tears: defensin expression after ocular surface surgery. J Proteome Res 2004;3:410-416.
96. Hida RY, Ohashi Y, Takano Y, Dogru M, Goto E, Fujishima H, Saito I, Saito K, Fukase Y, Tsubota K: Elevated levels of human alpha-defensin in tears of patients with allergic conjunctival disease complicated by corneal lesions: detection by SELDI ProteinChip system and quantification. Curr Eye Res 2005;30:723-730.
97. Hattenbach LO, Gumbel H, Kippenberger S: Identification of beta-defensins in human conjunctiva. Antimicrob Agents Chemother 1998;42:3332.
98. McNamara NA, Van R, Tuchin OS, Fleiszig SMJ: Ocular surface epithelia express mRNA for human beta defensin-2. Exp Eye Res 1999;69:483-490.
99. Lehmann OJ, Hussain IR, Watt PJ: Investigation of β-defensin gene expression in the ocular anterior segment by semiquantitative RT-PCR. Br J Ophthalmol 2000;84:523-526.
100. McDermott AM, Redfern RL, Zhang B, Pei Y, Huang L, Proske RJ: Defensin expression by the cornea: multiple signaling pathways mediate IL-1beta stimulation of hBD-2 expression by corneal epithelial cells. Invest Ophthalmol Vis Sci 2003;44:1859-1865.
101. Narayanan S, Miller WL, McDermott AM: Expression of human β-defensins in conjunctival epithelium: relevance to dry eye disease. Invest Ophthalmol Vis Sci 2003;44:3795-3801.
102. Kumar A, Yin J, Zhang J, Yu FSX: Modulation of corneal epithelial innate immune response to Pseudomonas infection by flagellin pretreatment. Invest Ophthalmol Vis Sci 2007;48:4664-4670.
103. Kumar A, Zhang J, Yu FS: Innate immune response of corneal epithelial cells to Staphylococcus aureus infections: role of peptidoglycan in stimulating proinflammatory cytokine secretion. Invest Ophthalmol Vis Sci 2004;45:3513-3522.
104. Kumar A, Zhang J, Yu FS: Toll-like receptor 2-mediated expression of beta-defensin-2 in human corneal epithelial cells. Microbes Infect 2006;8:380-389.
105. Shin JS, Kim CW, Kwon YS, Kim JC: Human beta-defensin 2 is induced by interleukin-1 beta in the corneal epithelial cells. Exp Mol Med 2004;36:204-210.
106. McDermott AM, Redfern RL, Zhang B: Human β-defensin 2 is up-regulated during re-epithelialization of the cornea. Curr Eye Res 2001;22:64-67.
107. Kawasaki S, Kawamoto S, Yokoi N, Connon C, Minesaki Y, Kinoshita S, Okubo K: Upregulated gene expression in the conjunctival epithelium of patients with Sjögren's syndrome. Exp Eye Res 2003;77:17-26.
108. McIntosh RS, Cade JE, Al-Abed M, Shanmuganathan V, Gupta R, Bhan A, Tighe PJ, Dua HS: The spectrum of antimicrobial peptide expression at the ocular surface. Invest Ophthalmol Vis Sci 2005;46:1379-1385.
109. Nomura I, Goleva E, Howell MD, Hamid QA, Ong PY, Hall CF, Darst MA, Gao B, Boguniewicz M, Travers JB, Leung DY: Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol 2003;171:3262-3269.
110. Huang LC, Jean D, Proske RJ, Reins RY, McDermott AM: Ocular surface expression and in vitro activity of antimicrobial peptides. Curr Eye Res 2007;32:595-609.
111. Abedin A, Mohammed I, Hopkinson A, Dua HS: A novel antimicrobial peptide on the ocular surface shows decreased expression in inflammation and infection. Invest Ophthalmol Vis Sci 2008;49:28-33.
112. Huang LC, Redfern RL, Narayanan S, Reins RY, McDermott AM: In vitro activity of human beta-defensin 2 against Pseudomonas aeruginosa in the presence of tear fluid. Antimicrob Agents Chemother 2007;51:3853-3860.
113. Gordon YJ, Huang LC, Romanowski EG, Yates KA, Proske RJ, McDermott AM: Human cathelicidin (LL-37), a multifunctional peptide, is expressed by ocular surface epithelia and has potent antibacterial and antiviral activity. Curr Eye Res 2005;30:1-10.
114. Huang LC, Petkova TD, Reins RY, Proske RJ, McDermott AM: Multifunctional roles of human cathelicidin (LL-37) at the ocular surface. Invest Ophthalmol Vis Sci 2006;47:2369-2380.
115. Martins SA, Castro-Combs J, Camacho W, Wittmann P, Hicks JL, De Marzo AM, E berhart CG, Behrens A: Dermcidin expression in the eye - potential protective mechanisms against ocular bacterial invasion. Invest Ophthalmol Vis Sci 2008;49:ARVO E-abstract 836.
116. Steele PS, Jumblatt MM: Defense proteins of the ocular surface. Invest Ophthalmol Vis Sci 2004;45:ARVO E-abstract 3792.
117. Spandau UH, Toksoy A, Verhaart S, Gillitzer R, Kruse FE: High expression of chemokines Gro-alpha (CXCL-1), IL-8 (CXCL-8), and MCP-1 (CCL-2) in inflamed human corneas in vivo. Arch Ophthalmol 2003;121:825-831.
118. Steele PS, Jumblatt MM, Smith NB, Pierce WM: Detection of histatin5 in normal human schirmer strip samples by mass spectroscopy. Invest Ophthalmol Vis Sci 2002;43:ARVO E-abstract 98.
119. Stoeckelhuber M, Messmer EM, Schubert C, Stoeckelhuber BM, Koehler C, Welsch U, Bals R: Immunolocalization of defensins and cathelicidin in human glands of Moll. Ann Anat 2008;190:230-237.
120. Schibli DJ, Hunter HN, Aseyev B, Starner TD, Wieneck JM, McCray PB Jr, Tack BF, Vogel HJ: The solution structures of the human beta-defensins lead to a better understanding of the potent bactericidal activity of hBD-3 against Staphylococcus aureus . J Biol Chem 2002;277:8279-8289.
121. Dorschner RA, Lopez-Garcia B, Peschel A, Krause D, Morikawa K, Nizet V, Gallo RL: The mammalian ionic environment dictates microbial susceptibility to antimicrobial defense peptides. FASEB J 2006;20:35-42.
122. Matsuzaki K, Sugishita K, Fujii N, Miyajima K: Molecular basis for membrane selectivity of an antimicrobial peptide, magainin 2. Biochemistry 1995;34:3423-3429.
123. Tytler EM, Anantharamaiah GM, Walker DE, Mishra VK, Palgunachari MN, Segrest JP: Molecular basis for prokaryotic specificity of magainin-induced lysis. Biochemistry 1995;34:4393-4401.
124. Shai Y: Mode of action of membrane active antimicrobial peptides. Biopolymers 2002; 66:236-248.
125. van't Hof W, Veerman ECI, Helmerhorst EJ, Amerongen AV: Antimicrobial peptides: properties and applicability. Biol Chem 2001;382:597-619.
126. Matsuzaki K, Murase O, Fujii N, Miyajima K: An antimicrobial peptide, magainin 2, induced rapid flip-flop of phospholipids coupled with pore formation and peptide translocation. Biochemistry 1996;35:11361-11368.
127. Yang L, Harroun TA, Weiss TM, Ding L, Huang HW: Barrel-stave model or toroidal model? A case study on melittin pores. Biophys J 2001;81:1475-1485.
128. Bechinger B, Lohner K: Detergent-like actions of linear amphipathic cationic antimicrobial peptides. Biochim Biophys Acta 2006;1758:1529-1539.
129. Pkorny A, Almeida PFF: Kinetics of dye efflux and lipid flip-flop induced by delta-lysin in phosphatidylcholine vesicle and the mechanism of graded release by amphipathic, alpha-helical peptides. Biochemistry 2004;43:8846-8857.
130. Miteva M, Anderson M, Karshikoff A, Otting G: Molecular electroporation: a unifying concept for the description of membrane pore formation by antibacterial peptides, exemplified with NK-lysin. FEBS Lett 1999;462:155-158.
131. Lehrer RI, Barton A, Daher KA, Harwig SS, Ganz T, Selsted ME: Interaction of human defensins with Escherichia coli. Mechanism of bactericidal activity. J Clin Invest 1989;84:553-561.
132. Skerlavaj B, Romeo D, Gennaro R: Rapid membrane permeabilization and inhibition of vital functions of gram-negative bacteria by bactenecins. Infect Immun 1990;58:3724-3730.
133. Boman HG, Agerberth B, Boman A: Mechanism of action on Escherichia coli of cecropin Pa and PR-39, two antibacterial peptides from pig intestine. Infect Immun 1993;62:2978-2984.
134. Brotz H, Bierbaum G, Leopold K, Reynolds PE, Sahl HG: The lantibiotic mersacidin inhibits peptidoglycan synthesis by targeting lipid II. Antimicrob Agents Chemother 1998;42:154-160.
135. Subbalakshmi C, Sitaram N: Mechanism of antimicrobial action of indolicidin. FEMS Microbiol Lett 1998;160:91-96.
136. Oh J, Cajal Y, Skowronska EM, Belkin S, Chen J, Van Dyk TK, Sasser M, Jain MK: Cationic peptide antimicrobials induce selective transcription of micF and osmY in Escherichia coli. Biochim Biophys Acta 2000;1463:43-54.
137. Otvos L Jr, O I, Rogers ME, Consolvo PJ, Condie BA, Lovas S, Bulet P, Blaszczyk-Thurin M: Interaction between heat shock proteins and antimicrobial peptides. Biochemistry 2000;39:14150-14159.
138. Kragol G, Lovas S, Varadi G, Condie BA, Hoffmann R, Otvos L: The antibacterial peptide pyrrhocoricin inhibits the ATPase actions of DnaK and prevents chaperone-assisted protein folding. Biochemistry 2001;40:3016-3026.
139. Patrzykat A, Friedrich CL, Zhang L, Mendoza V, Hancock RE: Sublethal concentrations of pleurocidin-derived antimicrobial peptides inhibit macromolecular synthesis in Escherichia coli. Antimicrob Agents Chemother 2002;46:605-614.
140. Brogden KA: Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol 2005;3:238-250.
141. Hale JD, Hancock RE: Alternative mechanisms of action of cationic antimicrobial peptides on bacteria. Expert Rev Anti Infect Ther 2007;5:951-959.
142. Wimley WC, Selsted ME, White SH: Interactions between human defensins and lipid bilayers: evidence for formation of multimeric pores. Protein Sci 1994;3:1362-1373.
143. Hoover DM, Rajashankar KR, Blumenthal R, Puri A, Oppenheim JJ, Chertov O, Lubkowski J: The structure of human beta-defensin-2 shows evidence of higher order oligomerization. J Biol Chem 2000;275:32911-32918.
144. Wu Z, Hoover DM, Yang D, Boulegue C, Santamaria F, Oppenheim JJ, Lubkowski J, Lu W: Engineering disulfide bridges to dissect antimicrobial and chemotactic activities of human beta-defensin-3. Proc Natl Acad Sci USA 2003;100:8880-8885.
145. Kluver E, Schulz-Maronde S, Scheid S, Meyer B, Forssmann WG, Adermann K: Structure-activity relation of human betadefensin 3: influence of disulfide bonds and cysteine substitution on antimicrobial activity and cytotoxicity. Biochemistry 2005;44:9804-9816.
146. Hoover DM, Wu Z, Tucker K, Lu W, Lubkowski J: Antimicrobial characterization of human β-defensin 3 derivatives. Antimicrob Agents Chemother 2003;47: 2804-2809.
147. Johansson J, Gudmundsson GH, Rottenberg ME, Berndt KD, Agerberth B: Conformation-dependent antibacterial activity of the naturally occurring human peptide LL-37. J Biol Chem 1998;273:3718-3724.
148. Oren Z, Lerman JC, Gudmundsson GH, Agerberth B, Shai Y: Structure and organization of the human antimicrobial peptide LL-37 in phospholipids membranes: relevance to the molecular basis for its non-cell-selective activity. Biochem J 1999;341:501-513.
149. Durr UHN, Sudheendra US, Ramamoorthy A: LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta 2006;1578:1408-1425.
150. Henzler Wildman KA, Lee DK, Ramamoorthy A: Mechanism of lipid bilayer disruption by the human antimicrobial peptide LL-37. Biochemistry 2003;42:6545-6558.
151. Neville F, Cahuzac M, Konovalov O, Ishitsuka Y, Lee KY, Kuzmenko I, Kale GM, Gidalevitz D: Lipid headgroup discrimination by antimicrobial peptide LL-37: insight into mechanism of action. Biophys J 2006;90:1275-1287.
152. Sevcsik E, Pabst G, Jilek A, Lohner K: How lipids influence the mode of action of membrane active peptides. Biochim Biophys Acta 2007;1768:2586-2595.
153. Li X, Li Y, Han H, Miller DW, Wang G: Solution structures of human LL-37 fragments and NMR-based identification of a minimal membrane-targeting antimicrobial and anticancer region. J Am Chem Soc 2006;128:5776-5785.
154. Feng Z, Jiang B, Chandra J, Ghannoum M, Nelson S, Weinberg A: Human beta-defensins: differential activity against Candidal species and regulation by Candida albicans . J Dent Res 2005;84:445-450.
155. den Hertog AL, van Marle J, van Veen HA, Van't Hof W, Bolscher JG, Veerman EC, Nieuw Amerongen AV: Candidacidal effects of two antimicrobial peptides: histatin 5 causes small membrane defects, but LL-37 causes massive disruption of the cell membrane. Biochem J 2005;388:689-695.
156. Lopez-Garcia B, Lee PH, Yamasaki K, Gallo RL: Anti-fungal activity of cathelicidins and their potential role in Candida albicans skin infection. J Invest Dermatol 2005;125:108-115.
157. Daher KA, Selsted ME, Lehrer RI: Direct inactivation of viruses by human granulocyte defensins. J Virol 1986;60:1068-1074.
158. Bastian A, Schafer H: Human alpha-defensin-1 (HNP-1) inhibits adenoviral infection in vitro. Regul Pept 2001;101:157-161.
159. Zhang L, Yu W, He T, Yu J, Caffrey RE, Dalmasso EA, Fu S, Pham T, Mei J, Ho JJ, Zhang W, Lopez P, Ho DD: Contribution of human alpha-defensins 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor. Science 2002;298:995-1000.
160. Shai Y, Makovitzky A, Avrahami D: Host defense peptides and lipopeptides: modes of action and potential candidates for the treatment of bacterial and fungal infections. Curr Protein Pept Sci 2006;7:479-486.
161. Klotman ME, Chang TL: Defensins in innate antiviral immunity. Nat Rev Immunol 2006;6:447-456.
162. Oren A, Ganz T, Liu L, Meerloo T: In human epidermis, β-defensin 2 is packaged in lamellar bodies. Exp Mol Pathol 2003;74:180-182.
163. Braff MH, Di Nardo A, Gallo RL: Keratinocytes store the antimicrobial peptide cathelicidin in lamellar bodies. J Invest Dermatol 2005;124:394-400.
164. Singh PK, Tack BF, McCray PB Jr, Welsh MJ: Synergistic and additive killing by antimicrobial factors found in human airway surface liquid. Am J Physiol Lung Cell Mol Physiol 2000;279:L799-L805.
165. Nagaoka I, Hirota S, Yomogida S, Ohwada A, Hirata M: Synergistic actions of antibacterial neutrophil defensins and cathelicidins. Inflamm Res 2000;49:73-79.
166. Chen X, Niyonsaba F, Ushio H, Okuda D, Nagaoka I, Ikeda S, Okumura K, Ogawa H: Synergistic effect of antibacterial agents human beta-defensins, cathelicidin LL-37 and lysozyme against Staphylococcus aureus and Escherichia coli. J Dermatol Sci 2005;40:123-132.
167. Huang LC, Reins RY, Gallo RL, McDermott AM: Cathelicidin-deficient (Cnlp-/-) mice show increased susceptibility to Pseudomonas aeruginosa keratitis. Invest Ophthalmol Vis Sci 2007;48:4498-4508.
168. Huang X, Du W, McClellen SA, Barrett RP, Hazlett LD: TLR4 is required for host resistance in Pseudomonas aeruginosa keratitis. Invest Ophthalmol Vis Sci 2006;47:4910-4916.
169. Kumar A, Hazlett LD, Yu FS: Flagellin suppresses the inflammatory response and enhances bacterial clearance in a murine model of Pseudomonas aeruginosa keratitis. Infect Immun 2008;76:89-96.
170. Khine AA, Del Sorbo L, Vaschetto R, Voglis S, Tullis E, Slutsky AS, Downey GP, Zhang H: Human neutrophil peptides induce interleukin-8 production through the P2Y6 signaling pathway. Blood 2006;107:2936-2942.
171. Syeda F, Liu HY, Tullis E, Liu M, Slutsky AS, Zhang H: Differential signaling mechanisms of HNP-induced IL-8 production in human lung epithelial cells and monocytes. J Cell Physiol 2008;214:820-827.
172. Yang D, Chertov O, Bykovskaia SN, Chen Q, Buffo MJ, Shogan J, Anderson M, Schröder JM, Wang JM, Howard OM, Oppenheim JJ: Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 1999;286:525-528.
173. Niyonsaba F, Ogawa H, Nagaoka I: Human beta-defensin-2 functions as a chemotactic agent for tumour necrosis factor-alpha-treated human neutrophils. Immunology 2004;111:273-281.
174. Funderburg N, Lederman MM, Feng Z, Drage MG, Jadlowsky J, Harding CV, Weinberg A, Sieg SF: Human-defensin-3 activates professional antigen-presenting cells via Toll-like receptors 1 and 2. Proc Natl Acad Sci USA 2007;104:18631-18635.
175. De Yang, Chen Q, Schmidt AP, Andersin GM, Wang JM, Wooters J, Oppenheim JJ, Chertov O: LL-37, the neutrophil granuleand epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL-1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes and T cells. J Exp Med 2000;192:1069-1074.
176. Tjabringa GS, Ninaber DK, Drijfhout JW, Rabe KF, Hiemstra PS: Human cathelicidin LL-37 is a chemoattractant for eosinophils and neutrophils that acts via formyl-peptide receptors. Int Arch Allergy Immunol 2006;140:103-112.
177. Koczulla R, von Degenfeld G, Kupatt C, Krotz F, Zahler S, Gloe T, Issbrucker K, Unterberger P, Zaiou M, Lebherz C, Karl A, Raake P, Pfosser A, Boekstegers P, Welsch U, Heimstra PS, Vogelmeier C, Gallo RL, Clauss M, Bals R: An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest 2003;111:1665-1672.
178. Tjabringa GS, Aarbiou J, Ninaber DK, Drijfhout JW, Sorensen OE, Borregaard N, Rabe KF, Hiemstra PS: The antimicrobial peptide LL-37 activates innate immunity at the airway epithelial surface by transactivation of the epidermal growth factor receptor. J Immunol 2003;171:6690-6696.
179. Elssner A, Duncan M, Gavrilin M, Wewers MD: A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1 beta processing and release. J Immunol 2004;172:4987-4994.
180. Nagaoka I, Tamura H, Hirata M: An antimicrobial cathelicidin peptide, human CAP18/LL-37, suppresses neutrophil apoptosis via activation of formyl-peptide receptor-like 1 and P2X7. J Immunol 2006;176:3044-3052.
181. Zhou L, Beuerman RW, Huang L, Barathi A, Foo YH, Li SF, Chea FT, Tan D: Proteomic analysis of rabbit tear fluid: defensin levels after an experimental corneal wound are correlated to wound closure. Proteomics 2007;7:3194-3206.
182. Kurpakus-Wheater M, Kernacki KA, Hazlett LD: Maintaining corneal integrity. How the 'window' stays clear. Prog Histochem Cytochem 2001;3:179-259.
183. Heilborn JD, Nilsson MF, Kratz G, Weber G, Sorensen O, Borregaard N, Stahle-Backdahl M: The cathelicidin antimicrobial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronis ulcer epithelium. J Invest Dermatol 2003;120:379-389.
184. Shaykhiev R, Beisswenger C, Kandler K, Senske J, Pucjner A, Damm T, Behr J, Bals R: Human endogenous antibiotic LL-37 stimulates airway epithelial cell proliferation and wound closure. Am J Physiol Lung Cell Mol Physiol 2005;289:L842-L848.
185. Redfern RL, Proske RJ, McDermott AM: Effect of defensins on corneal cell migration and cytokine production. Invest Ophthalmol Vis Sci 2004;45:ARVO E-abstract
186. 4866.
187. Li J, Beuerman R: Defensins augment the proinflammatory responses of human conjunctival epithelial cells. Invest Ophthalmol Vis Sci 2007;48:ARVO E-abstract 5312.
188. Li J, Shen JB, Tan D, Beuerman RW: Effect of HNP1 and HBD2 on cytokine gene expression in primary cultured human conjunctival epithelial cells. Invest Ophthalmol Vis Sci 2006;47:ARVO E-abstract 4377.
189. Li J, Raghunath M, Tan D, Lareu RR, Chen ZC, Beuerman RW: Defensins HNP1 and HBD2 stimulation of wound-associated responses in human conjunctival fibroblasts. Invest Ophthalmol Vis Sci 2006;47:3811-3819.
190. Gan L, Fagerholm P, Kim HJ: Effect of leukocytes on corneal cellular proliferation and wound healing. Invest Ophthalmol Vis Sci 1999;40:575-581.
191. Li Z, Burns A, Smith CW: Two waves of neutrophil emigration in response to corneal epithelial abrasion: distinct adhesion molecule requirements. Invest Ophthalmol Vis Sci 2006;47:1947-1955.
192. van den Berg RH, Faber-Krol MC, van Wetering S, Hiemstra PS, Daha MR: Inhibition of activation of the classical pathway of complement by human neutrophil defensins. Blood 1998;92:3898-3903.
193. Groeneveld TW, Ramwadhdoebe TH, Trouw LA, van den Ham DL, van der Borden V, Drijfhout JW, Hiemstra PS, Daha MR, Roos A: Human neutrophil peptide-1 inhibits both the classical and the lectin pathway of complement activation. Mol Immunol 2007;44:3608-3614.
194. Bhat S, Song YH, Lawyer C, Milner SM: Modulation of the complement system by human beta-defensin 2. J Burns Wounds 2007;5:e10.
195. Willcox MDP, Morris CA, Thakur A, Sack RA, Wickson J, Boey W: Complement and complement regulatory proteins in human tears. Invest Ophthalmol Vis Sci 1997;38:1-8.
196. Prohaszka Z, Nemet K, Csermely P, Hudecz F, Mezo G, Fust G: Defensins purified from human granulocytes bind C1q and activate the classical complement pathway like the transmembrane glycoprotein gp41 of HIV. Mol Immunol 1997;34:809-816.
197. Prohasxka Z, Fust G: Contribution of complement to defensin action in eye. Lancet 1998;352:451-452.
198. Befus AD, Mowat C, Gilchrist M, Hu J, Solomon S, Bateman A: Neutrophil defensins induce histamine secretion from mast cells: mechanisms of action. J Immunol 1999;163:947-953.
199. 2 production from mast cells. Eur J Immunol 2001;31:1066-1075.
200. Hamrah P, Dana MR: Corneal antigen-presenting cells. Chem Immunol Allergy 2007;92:58-70.
201. Chertov O, Michiel DF, Xu L, Wang JM, Tani K, Murphy WJ, Longo DL, Taub DD, Oppenheim JJ: Identification of defensin-1, defensin-2 and CAP37/azurocidin as T-cell chemoattractant proteins released from IL-8 stimulated neutrophils. J Biol Chem 1996;271:2935-2940.
202. Chaly YV, Paleolog EM, Kolesnikova TS, Tikhonov II, Petratchenko EV, Voitenok NN: Neutrophil alpha-defensin human neutrophil peptide modulates cytokine production in monocytes and adhesion molecule expression in endothelial cells. Eur Cytokine Netw 2000;11:257-266.
203. Boniotto M, Jordan WJ, Eskdale J, Tossi A, Antcheva N, Crovella S, Connell ND, Gallagher G: Human beta-defensin 2 induces a vigorous cytokine response in peripheral blood mononuclear cells. Antimicrob Agents Chemother 2006;50:1433-1441.
204. Zheng Y, Niyonsaba F, Ushio H, Nagaoka I, Ikeda S, Okumura K, Ogawa H: Cathelicidin LL-37 induces the generation of reactive oxygen species and release of human-alpha defensins from neutrophils. Br J Dermatol 2007;157:1124-1131.
205. Bowdish DM, Davidson DJ, Speert DP, Hancock REW: The human cationic peptide LL-37 induces activation of the extracellular signal-regulated kinase and p38 kinase pathways in primary human monocytes. J Immunol 2004;172:3758-3765.
206. Chavakis T, Cines DB, Rhee JS, Liang OD, Schubert U, Hammes HP, Higazi AA, Nawroth PP, Preissner KT, Bdeir K: Regulation of neovascularisation by human neutrophil peptides (alpha-defensins): a link between inflammation and angiogenesis. FASEB J 2004;18:1306-1308.
207. Economopoulou M, Bdeir K, Cines BD, Fogt F, Bdeir Y, Lubkowski J, Lu W, Preissner KT, Hammes HP, Chavakis T: Inhibition of pathologic retinal neovascularisation by alpha-defensins. Blood 2005;106:3831-3838.
208. Marr AK, Gooderham WJ, Hancock REW: Antibacterial peptides for therapeutic use: obstacles and realistic outlook. Curr Opin Pharmacol 2006;6:468-472.
209. Hancock REW, Sahl HG: Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 2006;24:1551-1557.
210. McPhee JB, Scott MG, Hancock REW: Design of host defence peptides for antimicrobial and immunity enhancing activities. Comb Chem High Throughput Screen 2005;8:257-272.
211. Liu S, Zhou L, Li J, Verma C, Foo YH, Yap EP, Tan DT, Beuerman RW: Linear analogues of human beta-defensin 3: concepts for design of antimicrobial peptides with reduced cytotoxicity to mammalian cells. Chembiochem 2008;9:964-973.
212. Nos-Barbera S, Portoles M, Morilla A, Ubach J, Andreu D, Paterson CA: Effect of hybrid peptides of cecropin A and melittin in an experimental model of bacterial keratitis. Cornea 1997;16:101-106.
213. Mannis M: The use of antimicrobial peptides in ophthalmology: an experimental study in corneal preservation and the management of bacterial keratitis. Trans Am Ophthalmol Soc 2002;100:243-271.
214. Brandt CR, Akkarawongsa R, Altmann S, Jose G, Kolb AW, Waring AJ, Lehrer RI: Evaluation of a theta-defensin in a murine model of herpes simplex virus type 1 keratitis. Invest Ophthalmol Vis Sci 2007;48:5118-5124.
215. Willcox M, Cole N, Lan J, Hume E, Aliwarga Y, Schubert T, Stapleton F, Sankaridurg P: Contact lenses coated with protamine reduce bacterial adhesion and the production of contact lens induced acute red eye (CLARE). Invest Ophthalmol Vis Sci 2004;45:ARVO E-abstract 1568.
216. Sousa LB, Mannis MJ, Schwab IR, Cullor J, Hosotani H, Smith W, Jaynes J: The use of synthetic cecropin (D5C) in disinfecting contact lens solutions. CLAO J 1996;22:114-117.
217. Schwab IR, Dries D, Cullor J, Smith W, Mannis M, Reid T, Murphy CJ: Corneal storage medium preservation with defensins. Cornea 1992;11:370-375.